<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02651220</url>
  </required_header>
  <id_info>
    <org_study_id>71491705</org_study_id>
    <nct_id>NCT02651220</nct_id>
  </id_info>
  <brief_title>Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study
      to Evaluate the Therapeutic Equivalence and Safety of adapalene and benzoyl peroxide gel,
      0.3%/2.5% (Actavis Laboratories UT, Inc.) to Epiduo® Forte (adapalene and benzoyl peroxide)
      gel 0.3%/2.5% (Galderma) in the treatment of Acne Vulgaris
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 1000 patients 12 to 40 years of age inclusive will be enrolled to have 870 patients in
      the modified intent-to-treat (mITT) population and 579 patients in the per-protocol (PP)
      population. The primary inclusion criteria are the presence of ≥ 20 inflammatory lesions
      (papules and pustules) and ≥ 25 non-inflammatory lesions (opened and closed comedones) and ≤
      2 nodulocystic lesions (i.e., nodules and cysts) on the face and an Investigator's Global
      Assessment (IGA) score of 3 or 4.

      Eligible patients will be randomized in a 1:1:1 ratio to one of the three treatments (Test,
      Reference or Placebo) on Visit 1. Patients will be instructed to apply the first treatment on
      the evening of enrollment into the study and then continue to apply once daily for the next
      83 days (for a total 84 days). Patients will attend the following scheduled clinic visits:

        -  Visit 1 - Screening/Baseline: Day 1

        -  Visit 2 - Interim Visit: Day 28 ± 4

        -  Visit 3 - Interim Visit: Day 56 ± 4

        -  Visit 4 - End of Study: Day 85 ± 4 Efficacy evaluations will be based on dermatological
           assessments in the clinic. The primary statistical analyses of interest are (1) the
           percent change from baseline to Week 12 in the number of inflamed (papules/pustules)
           lesions and non-inflamed (open and closed comedones) lesions. In addition, patients will
           also be evaluated by the Investigator to determine &quot;Clinical Success&quot; or &quot;Clinical
           Failure&quot; at Week 12
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline to Week 12 in the Number of Inflamed Lesions.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline to Week 12 in the Number of Non-inflamed Lesions.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With a Clinical Response of &quot;Clinical Success&quot; Using the Investigator's Global Assessment (IGA) at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Investigator's Global Assessment had to show a score of 0 (clear) or 1 (almost clear) to be considered a &quot;Clinical Success&quot;.
0= Clear skin with no inflammatory or non inflammatory lesions.
Almost clear, rare non-inflammatory lesions with no more than one small inflammatory lesion.
Mild severity; greater than Grade 1; some non inflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions).
Moderate severity; greater than Grade 2; up to many non inflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion.
Severe; greater than Grade 3, up to many non inflammatory lesions and may have some inflammatory lesions, but no more than a few nodular lesions.
Very severe, greater than Grade 4</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1001</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Epiduo® Forte Gel 0.3%/2.5% w/w</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (vehicle) Topical Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epiduo® Forte Gel</intervention_name>
    <description>Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</description>
    <arm_group_label>Epiduo® Forte Gel 0.3%/2.5% w/w</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene and Benzoyl Peroxide Gel</intervention_name>
    <description>Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</description>
    <arm_group_label>Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo gel</intervention_name>
    <description>vehicle used as placebo</description>
    <arm_group_label>Placebo (vehicle) Topical Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant, non-lactating female, ≥ 12 and ≤ 40 years of age with a clinical
             diagnosis of acne vulgaris.

          2. Signed informed consent form that meets all criteria of current FDA regulations. For a
             patient considered to be a minor in the state he/she lives and is enrolled, the
             patient parent or legal guardian will be required to sign the consent form and the
             patient will sign an IRB approved &quot;assent to participate&quot; form.

          3. Females of child bearing potential must not be pregnant or lactating at Visit 1 (as
             confirmed by a negative urine pregnancy test with a sensitivity of less than 25 mlU/mL
             or equivalent units of human chorionic gonadotropin). Women of childbearing potential
             must agree to the use of a reliable method of contraception (e.g., total abstinence,
             IUD, a double-barrier method [such as condom plus diaphragm with spermicide], oral,
             transdermal, injected or implanted non- or hormonal contraceptive), throughout the
             study. If the female is using a hormonal contraceptive, the same product must be taken
             for 3 months prior to Visit 1 and must agree not to replace with some other hormonal
             contraceptives during the study. A sterile sexual partner is not considered an
             adequate form of birth control.

             All females will be considered to be of childbearing potential unless they:

               -  Are post-menopausal, defined as women who have been amenorrheic for at least 12
                  consecutive months, without other known or suspected primary cause.

               -  Have been sterilized surgically or who are otherwise proven sterile (i.e., total
                  hysterectomy, or bilateral oophorectomy) with surgery at least 4 weeks prior to
                  Screening. Tubal ligation will not be considered a surgically sterile method.

             Female patients of childbearing potential are defined as:

               -  Females without prior hysterectomy, or who have had any evidence of menses in the
                  past 12 months.

               -  Females who have been amenorrhea for ≥ 12 months, but the amenorrhea is possibly
                  due to other causes, including prior chemotherapy, anti-estrogens, or ovarian
                  suppression.

          4. Have facial acne vulgaris with: ≥ 20 inflammatory lesions (i.e., papules and pustules)
             and ≥ 25 non-inflammatory lesions (i.e., open and closed comedones) and ≤ 2
             nodulocystic lesions (i.e., nodules and cysts).

          5. Have an Investigator's Global Assessment (IGA) score of 3 or 4 (see Appendix A).

          6. Willing to comply with the study requirements and restrictions including refraining
             from the use of all other topical acne medications or antibiotics during the 12 week
             treatment period.

          7. Patients who use make-up must have used the same brands/types for a minimum period of
             14 days before study entry and must agree to not change brand/type or frequency of use
             throughout the study.

        Exclusion Criteria:

          1. Patient has more than 2 facial nodular lesions; any nodules present will be documented
             but not included in the inflammatory and non-inflammatory lesion count for analysis.

          2. Patient has active cystic acne.

          3. Patient has acne conglobata, acne fulminans, or acne vulgaris requiring systemic
             treatment.

          4. Patient has a skin condition that would interfere with the diagnosis or assessment of
             acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell
             carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid
             folliculitis, bacterial folliculitis).

          5. Patients with excessive facial hair such as beards, sideburns, moustaches, etc. that
             would interfere with the diagnosis or assessment of acne.

          6. Patients with tattoos or excessive facial scarring that, in the Investigator's
             opinion, may interfere with the evaluation of the patient's acne.

          7. Patients with active facial sunburn, peeling from sunburn, or patients that will be
             exposed to excessive sunlight during the study.

          8. Females who are pregnant, lactating or likely to become pregnant during the study.

          9. History of allergy or hypersensitivity to adapalene, retinoids, benzoyl peroxide or
             history of any drug hypersensitivity or intolerance that, in the Investigator's
             opinion, would compromise the safety of the patient or the study.

         10. Significant history or current evidence of chronic infectious disease, system
             disorder, organ disorder or other medical condition that, in the Investigator's
             opinion, would place the study participant at undue risk by participation.

         11. Use of the following on the face within 1 month before Screening/Baseline:

               -  Cryodestruction or chemodestruction

               -  Dermabrasion

               -  Photodynamic therapy

               -  Acne surgery

               -  Intralesional steroids

               -  X-ray therapy

         12. Use of the following within 1 month before Screening/Baseline:

               -  Spironolactone

               -  Systemic steroids

               -  Systemic antibiotics

               -  Systemic anti-inflammatory agents (the use of acetylsalicylic acid for
                  prophylactic use up to 325 mg/day is allowed, provided that the patient is on a
                  stable dose and the regimen will remain constant throughout the study).
                  Acetaminophen will be allowed during the study with a maximum dose of 1g (i.e.,
                  1000 mg) twice daily and for a maximum of 3 consecutive days (its use is not
                  allowed within 1 week of each visit).

               -  Systemic treatment for acne vulgaris (other than oral retinoids that require a 6
                  month washout), including anti-androgens.

         13. Use of oral isotretinoin (Accutane®) or oral retinoids within 6 months, or therapeutic
             vitamin A supplements greater than 10,000 units/day (multivitamins are allowed).

         14. Use of the following on the face within 2 weeks before Screening/Baseline:

               -  Topical steroids

               -  Topical retinoids

               -  Topical zinc

               -  Topical anti-inflammatory agents (including salicylic acid)

               -  Topical antibiotics (including antibacterials)

               -  Benzoyl peroxide

               -  Any other topical over-the-counter preparations for acne treatment

         15. Use of the following on the face within 1 week before Screening/Baseline:

               -  Phototherapy devices for acne (e.g., ClearLightTM)

               -  Medicated cleansers including adhesive cleansing strips

               -  Cosmetic procedures (i.e., facials, peeling, comedone extraction) and
                  alpha-hydroxy/glycolic acid

         16. Receipt of any drug as part of a research study within 30 days.

         17. Female patients taking hormonal contraceptives or oral estrogen for less than three
             months and those that plan to change the dosage regimen during the course of the
             study.

         18. Previous participation in this study.

         19. Employees of the Investigator or research center or their immediate family members.

         20. Patients who are illiterate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 103</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 109</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 112</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 110</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 111</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>92210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 104</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 113</name>
      <address>
        <city>West Covina</city>
        <state>California</state>
        <zip>91790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 101</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 119</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 114</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 115</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 116</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 102</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 105</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 120</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 107</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 106</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 108</name>
      <address>
        <city>Rhinelander</city>
        <state>Wisconsin</state>
        <zip>54501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 117</name>
      <address>
        <city>Belize City</city>
        <country>Belize</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 118</name>
      <address>
        <city>Belize City</city>
        <country>Belize</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belize</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2016</study_first_posted>
  <results_first_submitted>May 22, 2020</results_first_submitted>
  <results_first_submitted_qc>June 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2020</results_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adapalene</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1001 patients were randomized, 24 did not receive any study medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</title>
          <description>Generic: Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</description>
        </group>
        <group group_id="P2">
          <title>Epiduo® Forte Gel 0.3%/2.5% w/w</title>
          <description>Reference: Epiduo® Forte Gel: Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</description>
        </group>
        <group group_id="P3">
          <title>Vehicle Topical Gel</title>
          <description>Placebo gel: vehicle used as placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="337"/>
                <participants group_id="P2" count="335"/>
                <participants group_id="P3" count="329"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="314"/>
                <participants group_id="P2" count="308"/>
                <participants group_id="P3" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Parent/Guardian</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Data is presented here for the Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</title>
          <description>Generic: Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</description>
        </group>
        <group group_id="B2">
          <title>Epiduo® Forte Gel 0.3%/2.5% w/w</title>
          <description>Reference: Epiduo® Forte Gel: Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</description>
        </group>
        <group group_id="B3">
          <title>Vehicle Topical Gel</title>
          <description>Placebo gel: vehicle used as placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="332"/>
            <count group_id="B2" value="323"/>
            <count group_id="B3" value="322"/>
            <count group_id="B4" value="977"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.5" spread="7.1"/>
                    <measurement group_id="B2" value="22.5" spread="7.1"/>
                    <measurement group_id="B3" value="22.5" spread="7.0"/>
                    <measurement group_id="B4" value="22.5" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="215"/>
                    <measurement group_id="B4" value="614"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="134"/>
                    <measurement group_id="B4" value="421"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="188"/>
                    <measurement group_id="B4" value="556"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="348"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="175"/>
                    <measurement group_id="B4" value="548"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline to Week 12 in the Number of Inflamed Lesions.</title>
        <time_frame>12 weeks</time_frame>
        <population>Using the Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</title>
            <description>Generic: Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</description>
          </group>
          <group group_id="O2">
            <title>Epiduo® Forte Gel 0.3%/2.5% w/w</title>
            <description>Reference: Epiduo® Forte Gel: Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Topical Gel</title>
            <description>Placebo gel: vehicle used as placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in the Number of Inflamed Lesions.</title>
          <population>Using the Per Protocol Population</population>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="281"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-74.2" spread="25.0"/>
                    <measurement group_id="O2" value="-73.0" spread="27.8"/>
                    <measurement group_id="O3" value="-30.6" spread="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was based on 90% confidence interval within 80-125%.</non_inferiority_desc>
            <param_type>Bioavailability</param_type>
            <param_value>100.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.78</ci_lower_limit>
            <ci_upper_limit>103.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline to Week 12 in the Number of Non-inflamed Lesions.</title>
        <time_frame>12 weeks</time_frame>
        <population>Using the Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</title>
            <description>Generic: Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</description>
          </group>
          <group group_id="O2">
            <title>Epiduo® Forte Gel 0.3%/2.5% w/w</title>
            <description>Reference: Epiduo® Forte Gel: Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Topical Gel</title>
            <description>Placebo gel: vehicle used as placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in the Number of Non-inflamed Lesions.</title>
          <population>Using the Per Protocol Population</population>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="281"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65.4" spread="25.7"/>
                    <measurement group_id="O2" value="-64.5" spread="26.0"/>
                    <measurement group_id="O3" value="-25.5" spread="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence is based on 90% confidence interval within 80-125%.</non_inferiority_desc>
            <param_type>Bioavailability</param_type>
            <param_value>99.73</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.04</ci_lower_limit>
            <ci_upper_limit>103.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With a Clinical Response of &quot;Clinical Success&quot; Using the Investigator's Global Assessment (IGA) at Week 12</title>
        <description>The Investigator's Global Assessment had to show a score of 0 (clear) or 1 (almost clear) to be considered a &quot;Clinical Success&quot;.
0= Clear skin with no inflammatory or non inflammatory lesions.
Almost clear, rare non-inflammatory lesions with no more than one small inflammatory lesion.
Mild severity; greater than Grade 1; some non inflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions).
Moderate severity; greater than Grade 2; up to many non inflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion.
Severe; greater than Grade 3, up to many non inflammatory lesions and may have some inflammatory lesions, but no more than a few nodular lesions.
Very severe, greater than Grade 4</description>
        <time_frame>12 weeks</time_frame>
        <population>Using the Modified Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</title>
            <description>Generic: Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</description>
          </group>
          <group group_id="O2">
            <title>Epiduo® Forte Gel 0.3%/2.5% w/w</title>
            <description>Reference: Epiduo® Forte Gel: Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Topical Gel</title>
            <description>Placebo gel: vehicle used as placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Clinical Response of &quot;Clinical Success&quot; Using the Investigator's Global Assessment (IGA) at Week 12</title>
          <description>The Investigator's Global Assessment had to show a score of 0 (clear) or 1 (almost clear) to be considered a &quot;Clinical Success&quot;.
0= Clear skin with no inflammatory or non inflammatory lesions.
Almost clear, rare non-inflammatory lesions with no more than one small inflammatory lesion.
Mild severity; greater than Grade 1; some non inflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions).
Moderate severity; greater than Grade 2; up to many non inflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion.
Severe; greater than Grade 3, up to many non inflammatory lesions and may have some inflammatory lesions, but no more than a few nodular lesions.
Very severe, greater than Grade 4</description>
          <population>Using the Modified Intent to Treat Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="331"/>
                <count group_id="O2" value="321"/>
                <count group_id="O3" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to at least 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</title>
          <description>Generic: Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</description>
        </group>
        <group group_id="E2">
          <title>Epiduo® Forte Gel 0.3%/2.5% w/w</title>
          <description>Reference: Epiduo® Forte Gel: Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w</description>
        </group>
        <group group_id="E3">
          <title>Vehicle Topical Gel</title>
          <description>Placebo gel: vehicle used as placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="332"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Motion sickness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site dryness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Application site hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Application site irritation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="332"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Multiple allergies</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="332"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="323"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="332"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="323"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Pulmonary contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Musckuloskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Heachache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="332"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Pelvic fluid collection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="332"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Skin tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director, CE Studies</name_or_title>
      <organization>Teva Pharmaceuticals USA, Inc.</organization>
      <phone>1-888-483-8279</phone>
      <email>USMedInfo@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

